Paper856436
Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model.
Cvitkovic E and 4 others. Cancer, 1977. Cited by 234 papers, by iCite.
Cite this record
ConductScience Library. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Papers, record 856436. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/856436
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Mannitol | Major topic |
| Animals | |
| Bone Marrow | |
| Diuresis | |
| Dogs | |
| Infusions, Parenteral | |
| Injections, Intravenous | |
| Kidney |
Source PubMed
Cited by48
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 234 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40465128 | Guidance on the short hydration method for cisplatin administration. | Int J Clin Oncol | 2025 | https://conductscience.org/library/papers/40465128 | PubMed |
| 38564107 | Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial. | Int J Clin Oncol | 2024 | https://conductscience.org/library/papers/38564107 | PubMed |
| 38457231 | Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial. | Cancer Med | 2024 | https://conductscience.org/library/papers/38457231 | PubMed |
| 37382749 | Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. | Int J Clin Oncol | 2023 | https://conductscience.org/library/papers/37382749 | PubMed |
| 36964641 | Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide for Intraperitoneal Mesothelioma in Severe Renal Impairment: A Case Report. | Am J Case Rep | 2023 | https://conductscience.org/library/papers/36964641 | PubMed |
| 35436142 | The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial. | JCO Glob Oncol | 2022 | https://conductscience.org/library/papers/35436142 | PubMed |
| 33805488 | Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33805488 | PubMed |
| 32757852 | Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity. | Expert Opin Drug Metab Toxicol | 2020 | https://conductscience.org/library/papers/32757852 | PubMed |
| 32740717 | Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study. | Int J Clin Oncol | 2020 | https://conductscience.org/library/papers/32740717 | PubMed |
| 32489432 | Cisplatin-induced renal toxicity in elderly people. | Ther Adv Med Oncol | 2020 | https://conductscience.org/library/papers/32489432 | PubMed |
| 31831529 | Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial. | BMJ Open | 2019 | https://conductscience.org/library/papers/31831529 | PubMed |
| 30167970 | Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study. | Int J Clin Pharm | 2018 | https://conductscience.org/library/papers/30167970 | PubMed |
| 29770217 | Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database. | SAGE Open Med | 2018 | https://conductscience.org/library/papers/29770217 | PubMed |
| 29504819 | Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation. | Cancer Biol Ther | 2018 | https://conductscience.org/library/papers/29504819 | PubMed |
| 29503734 | Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. | ESMO Open | 2018 | https://conductscience.org/library/papers/29503734 | PubMed |
| 28856465 | Guidelines for treatment of renal injury during cancer chemotherapy 2016. | Clin Exp Nephrol | 2018 | https://conductscience.org/library/papers/28856465 | PubMed |
| 26093520 | Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. | Int J Clin Oncol | 2016 | https://conductscience.org/library/papers/26093520 | PubMed |
| 25789143 | Protective effect of hydroalcoholic extract of tribulus terrestris on Cisplatin induced renal tissue damage in male mice. | Int J Prev Med | 2015 | https://conductscience.org/library/papers/25789143 | PubMed |
| 25472655 | Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study. | BMC Pharmacol Toxicol | 2014 | https://conductscience.org/library/papers/25472655 | PubMed |
| 25032734 | Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma. | Br J Cancer | 2014 | https://conductscience.org/library/papers/25032734 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/856436
GET https://conductscience.org/api/papers/v1/856436/cited_by?page=2